7′-Substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitors

Journal of Medicinal Chemistry

Volumn 49, Issue 17, 2006, Pages 5352-5362

  Zhang, Lin ^a   Fan, Junhua ^a   Vu, Khang ^a   Hong, Kevin ^a   Le Brazidec, Jean Yves ^a   Shi, Jiandong ^a   Biamonte, Marco ^a   Busch, David J ^a   Lough, Rachel E ^a   Grecko, Roy ^a   Ran, Yingqing ^a   Sensintaffar, John L ^a   Kamal, Adeela ^a   Lundgren, Karen ^a   Burrows, Francis J ^a   Mansfield, Robert ^a   Timony, Gregg A ^a   Ulm, Edgar H ^a   Kasibhatla, Srinivas R ^a   Boehm, Marcus F ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 (7 CHLOROBENZOTHIAZOL 2 YLSULFANYL) 9 (2 CYCLOPROPYLAMINOETHYL) 9H PURIN 6 YLAMINE; [2 [6 AMINO 8 (7 CHLOROTHIAZOLO[4,5 C]PYRIDIN 2 YLSULFANYL)PURIN 9 YL]ETHYL]PHOSPHONIC ACID DIETHYL ESTER; ACETIC ACID 2 [6 AMINO 8 (7 CHLOROBENZOTHIAZOL 2 YLSULFANYL)PURIN 9 YL]PROPYL ESTER; AROMATIC COMPOUND; BENZOTHIAZOLE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90 INHIBITOR; PURINE DERIVATIVE; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; HEAT SHOCK PROTEIN 90; THIOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CANCER MODEL; CONCENTRATION RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN DEGRADATION; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT; ANIMAL; BINDING SITE; BREAST TUMOR; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; NUDE MOUSE; STEREOISOMERISM; TIME; TUMOR CELL LINE;

ANIMALS; BINDING SITES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MICE; MICE, NUDE; MOLECULAR STRUCTURE; PURINES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFHYDRYL COMPOUNDS; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33747500679     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm051146h     Document Type: Article

References (31)

1. Whitesell, L.; Lindquist, S. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 5, 761-772.
2. Tago, K.; Tsukahara, F.; Naruse, M.; Yoshioks, T.; Takano, K. HSP90 inhibitors attenuate effect of dexamethasone on activated NF-kB and AP-1. Life Sci. 2004, 74, 1981-1992.
3. Dunber, A. Y.; Kamada, Y.; Jenkins, G. J.; Lowe, E. R.; Billecke, S.; Osawa, Y. Ubiquitination and degradation of neuronal nitric-oxide synthase in vitro: dimer stabilization protects the enzyme from proteolysis. Mol. Pharmacol. 2004, 66, 964-969.
4. Laufa, U. Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur. J. Clin. Pharmacol. 2003, 58, 719-732.
5. Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M. F.; Fritz, L. C.; Burrows, F. J. A high-affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors. Nature 2003, 425 (6956), 407-410.
6. DeBoer, C.; Meulman, P. A.; Wnuk, R. J.; Peterson, D. H. Geldanamycin, a new antibiotic. J. Antibiot. 1970, 23, 442-447.
7. (a) Johnson, R. D.; Haber, A.; Rinehart, K. Geldanamycin biosynthesis and carbon magnetic resonance. J. Am. Chem. Soc. 1974, 96 (10), 3316-3317.
8. (b) Whitesell, L.; Mimnaugh, E. G.; De Costa, B.; Myers, C. E.; Neckers, L. M. Inhibition of heat shock protein HSP90-pp60vsrc heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 8324-8328.
9. Schneider, C.; Sepp-Lorenzino, L.; Nimmesgern, E.; Ouerfelli, O.; Danishefsky, S.; Rosen, N.; Haiti, F. U. Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 14536-14541.
10. Solit, D. B.; Zheng, M. D.; Münster, P. N.; Higgins, B.; Verbel, D.; Heller, G.; Tong, W.; Cordon-Cardo, C.; Agus, D. B.; Scher, H. I.; Rosen, N. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res. 2002, 8, 986-993.
11. Neckers, L.; Schulte, T. W.; Mimnaugh, E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest. New Drugs 1999, 17, 361-373.
12. Erlichman, C.; Toft, D.; Reid, J.; Sloan, J.; Atherton, P.; Adjei, A.; Ames, M.; Croghan, G. A phase I trial of 17-allyl-amino-geldanamycin in patients with advanced cancer. Proc. Am. Assoc. Cancer Res. 2001, 42, abstract 4474.
13. (a) Maloney, A.; Workman, P. Hsp90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther. 2002, 2, 3-24.
14. (b) Janin, Y. L. Heat shock protein 90 inhibitors. A text book example of medicinal chemistry? J. Med. Chem. 2005, 48, 7503-7512.
15. Chiosis, G.; Lucas, B.; Huezo, S. A.; Huezo, H.; Rosen, N. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of HER-2 tyrosine kinase. Bioorg. Med. Chem. 2002, 10, 3555-3564.
16. Chiosis, G.; Timaul, M. N.; Lucas, B.; Munster, P. N.; Zheng, F. F.; Lorenzino, L. S.; Rosen, N. A small molecular designed to bind to the adenine nucleotide pocket of HSP90 causes HER-2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol. 2001, 8, 289-299.
17. Chiosis, G.; Lucas, B.; Shtil, A.; Huezo, H.; Rosen, N. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of HER-2 tyrosine kinase. Bioorg. Med. Chem. Lett. 2002, 10, 3555-3564.
18. Liauger, L.; He, H.; Kim, J.; Aguirre, J.; Rosen, N.; Peters, U.; Davies, P.; Chiosis, G. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. J. Med. Chem. 2005, 48, 2892-2905.
19. Drysdale, M. J.; Dymock, B. W.; Barril-Alonso, X.; Workman, P.; Pearl, L. H.; Prodromou, C.; MacDonald, E. 3,4-Diarylpyrazoles and their use in the therapy of cancer. PCT International Application WO03055860, 2003.
20. Dymock, B.; Barril, X.; Beswick, M.; Collier, A.; Davies, N.; Drysdale, M.; Fink, A.; Fromont, C.; Hubbard, R. E.; Massey, A.; Surgenor, A.; Wright, L. Adenine derived inhibitors of the molecular chaperone HSP90-SAR explained through multiple X-ray structures. Bioorg. Med. Chem. Lett. 2004, 14, 325-328.
21. Kasibhatla, S. R.; Zhang, L.; Boehm, M. F.; Fan, J.; Hong, K.; Shi, J.; Biamonte, M. A. Purine analogues having Hsp90 inhibiting activity. Patent WO3037860, 2003.
22. Biamonte, M. A.; Shi, J. D.; Hong, K.; Hurst, D. C.; Zhang, L.; Fan, J. F.; Busch, D. J.; Karjian, P. L.; Maldonado, A. A.; Sensintaffar, J. L.; Yang, Y. C.; Kamal, A.; Lough, R. E.; Lundgren, K.; Burrows, F. J.; Timony, G. A.; Boehm, M. F.; Kasibhatla, S. R. Orally active purine-based inhibitors of Hsp90. J. Med. Chem. 2006, 49, 817-828.
23. Janeba, Z.; Holy, A.; Masojidkova, M. Synthesis of acyclic nucleoside and nucleotide analogues derived from 6-amino-7H-purin-8-(9H)-one. Collect. Czech. Chem. Commun. 2000, 65 (7), 1109-1125.
24. Fujii, T.; Saito, T.; Fujisawa, T. Alternative syntheses of azepinomycin. Heterocycles 1988, 27 (5), 1163-1166.
25. Fujii, T.; Saito, T.; Mori, S. Purines. XLIII. A total synthesis of the marine sponge base 6-imino-1,9-dimethyl-8-oxopurine. Chem. Pharm. Bull. 1990, 38 (8), 2146-2150.
26. Chaudhun, N. C. Convenient strategies for the preparation of modified 2(3H)-benzolethiones. Synth. Commun. 1996, 26 (20), 3783-3790.
27. 2x-receptors. Eur. J. Med. Chem. 1988, 23, 433-439.
28. Nantka-Namirski, P. Synteza karbolin metoda graebe-ullmanna. I. Acta Pol. Pharm. 1961, 18, 391-399.
29. Robins, R. K. Potential purine antagonists. IX. Further studies of some 4,6-disubstituted pyrazolo[3,4-d]pyrimidines. J. Am. Chem. Soc. 1957, 79, 6407-6415.
30. Le Brazidec, J.-Y.; Kamal, A.; Busch, D.; Thao, L.; Zhang, L.; Timony, G.; Grecko, R.; Trent, K.; Lough, R.; Salazar, T.; Khan, S.; Burrows, F.; Boehm, M. F. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90. J. Med. Chem. 2004, 47, 3865-3873.
31. Sienkowska, M.; Benin, V.; Kaszynski, P. Preparation and NMR analysis of 2,6-heterodifunctional halobenzenes as precursors for substituted biphenyls. Tetrahedron 2000, 56, 165-173.